AXA1125

AXA1125 or LIVRQNac is a new drug developed by Axcella Therapeutics which is currently in clinical trials for post-exertional fatigue caused by Long COVID. AXA1125 has been described as a "novel composition of amino acids" and a "metabolic modulator" and consists of five amino acids (arginine, glutamine, isoleucine, leucine, and valine) and N-acetylcysteine (NAC).

Theory
AXA1125 is a endogenous metabolic modulator, which means it consists of naturally occurring substances that act in a way that modulates energy metabolism. AXA1125 was designed to treat non-alcoholic liver conditions.

Amino acids and precusors
AXA1125 consists of a combination of:
 * Arginine
 * Glutamine
 * Isoleucine
 * Leucine
 * Valine
 * N-acetylcysteine (NAC), a precursor to several amino acids

Learn more

 * Oxford test potential treatment for fatigue in long COVID patients - Oxford University
 * Poster: Mechanistic Insights Into AXA1125, a Novel Endogenous Metabolic Modulator Composition, Targeting Multiple NASH Drivers - Axcella Health Inc.